Associated Papers
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia.
Chen C et al.
Pharmacogenomics and Personalized Medicine, 2024
SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.
Perea-Jacobo R et al.
Tuberculosis (edinburgh, Scotland), 2022
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Franczyk B et al.
Genes, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms.
Choudhuri S et al.
Toxicology and Applied Pharmacology, 2020
Study of Caspase 8 mutation in oral cancer and adjacent precancer tissues and implication in progression.
Singh R et al.
Plos One, 2020
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?
Chen J et al.
Clinical and Translational Science, 2018
Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.
Mladenovska K et al.
Die Pharmazie, 2017
Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.
Medhasi S et al.
Neuropsychiatric Disease and Treatment, 2016
Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A et al.
Die Pharmazie, 2015
Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.
Grapci AD et al.
Balkan Journal of Medical Genetics : Bjmg, 2015
Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells.
Pu Z et al.
Oncology Reports, 2015
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.
Prasad B et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
Tamraz B et al.
Pharmacogenetics and Genomics, 2013
CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q et al.
Die Pharmazie, 2013
Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q et al.
Die Pharmazie, 2013
ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q et al.
Die Pharmazie, 2013
CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
Zhou Q et al.
Arzneimittel-forschung, 2012
The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
Hua WJ et al.
Cardiovascular Therapeutics, 2012
Genotyping of OATP2 Variants in a Group of Malaysian Neonates Using High-Resolution Melting Analysis.
Wong FL et al.
Bioresearch Open Access, 2012
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
Wen J et al.
Journal of Clinical Pharmacy and Therapeutics, 2010
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK et al.
European Journal of Clinical Pharmacology, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0